Figure 5.

Mean changes from baseline in patients' well-being over a median (range) of 194 (180 to 1,407) days during rituximab therapy in patients with various autoimmune diseases, as measured using the visual analogue scale (VAS; 0 to 100 mm) rated by the treating physician. VAS scores were not assessed in patients with mixed connective tissue disease or 'other' autoimmune diseases. AIHA, autoimmune haemolytic anaemia; AITP, autoimmune thrombocytopenia; AS, ankylosing spondylitis; MP, microscopic polyangiitis; NMO, neuromyelitis optica; PA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; WG, ANCA-associated granulomatous vasculitis.